Cargando…

Serous Retinopathy Associated With Combination MEK and Fibroblast Growth Factor Receptor Inhibitor

Purpose: To present a case of a chemotherapy regimen combining a fibroblast growth factor receptor (FGFR) and mitogen-activated protein kinase kinase (MEK) inhibitor leading to serous retinopathy. Methods: A retrospective chart review of a single case was performed. Results: A 67-year-old man with p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Day, H. Russell, Finn, Avni P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621699/ https://www.ncbi.nlm.nih.gov/pubmed/37927314 http://dx.doi.org/10.1177/24741264231163393

Ejemplares similares

Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor
por: Patel, Saagar N., et al.
Publicado: (2022)

Serous Retinal Detachment without Leakage on Fluorescein/Indocyanine Angiography in MEK Inhibitor-Associated Retinopathy
por: Murata, Chihiro, et al.
Publicado: (2022)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

A Case of Non-Resolving MEK Inhibitor-Associated Retinopathy
por: Chancellor, John R., et al.
Publicado: (2019)

New features in MEK retinopathy
por: Tyagi, Pallavi, et al.
Publicado: (2018)

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
por: Macklis, Paul, et al.
Publicado: (2020)

Rapidly Changing Serous Detachment During BRAF and MEK Inhibitor Therapy
por: Agata, Chisato, et al.
Publicado: (2021)

Central serous retinopathy associated with topical oral corticosteroid use: a case report
por: O’Brien, Preston, et al.
Publicado: (2019)

Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report
por: Kiraly, Peter, et al.
Publicado: (2022)

Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
por: Ahn, Jeffrey, et al.
Publicado: (2019)

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
por: Gershenson, David M., et al.
Publicado: (2020)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Photoreceptor disruption and vision loss associated with central serous retinopathy
por: Sun, Lynn W., et al.
Publicado: (2017)

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
por: Takekuma, Munetaka, et al.
Publicado: (2016)

Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma
por: Schoenberger, Scott D., et al.
Publicado: (2013)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
por: Alekseev, Oleg, et al.
Publicado: (2021)

Ayurvedic management central serous retinopathy - A case report
por: Shanti, K., et al.
Publicado: (2023)

LGG-63 MEK inhibitor-associated retinopathy (MEKAR) in a pediatric patient with an optic pathway glioma
por: Bendel, Anne, et al.
Publicado: (2022)

MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom
por: Groselli, S., et al.
Publicado: (2020)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
por: Han, Chanhee, et al.
Publicado: (2018)

Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate
por: Qian, Justin, et al.
Publicado: (2022)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

Steroid-induced central serous retinopathy
por: Shah, Samidh P., et al.
Publicado: (2011)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect
por: Negulescu, Miruna, et al.
Publicado: (2017)

Central serous retinopathy and hand–foot–mouth disease: coincidence or causation?
por: Taylor, Selina, et al.
Publicado: (2018)

A Masquerade Case: Choroidal Hemangioma Misdiagnosed As Central Serous Retinopathy
por: Lai, Leo, et al.
Publicado: (2023)

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
por: Fernandez, Marta Llaurado, et al.
Publicado: (2019)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies
por: Vinson, Kyle B., et al.
Publicado: (2020)

Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
por: Najjar, Omar, et al.
Publicado: (2020)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
por: Caruana, Marco, et al.
Publicado: (2020)

Neoplastic leptomeningeal disease masquerading as central serous retinopathy. A case report
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
por: Dai, Shuyan, et al.
Publicado: (2019)

Novel parameter for cancer chemosensitivity to fibroblast growth factor receptor inhibitors
por: Kitano, Shoichi, et al.
Publicado: (2022)

Fibroblast growth factor receptor 3‐mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition
por: Ban, Myung Jin, et al.
Publicado: (2018)

Serum Fibroblast Growth Factor 21 Levels Are Correlated with the Severity of Diabetic Retinopathy
por: Lin, Yuan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gikm54jn5c2fememfv60uehos2